INN: international nonproprietary name

An international nonproprietary name (INN) is the unique, public name the WHO assigns to an active substance so it can be identified worldwide.

Also known as: generic name, nonproprietary name, common name, rINN, international non-proprietary name

4 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Assigned by
The World Health Organization's INN Programme
Status
Public property; anyone may use it to identify the substance
Stems
Shared letter groups that mark a class, such as -pril, -olol and -tinib
In EU law
The common name in Article 1(21) of Directive 2001/83/EC

How it works

The International Nonproprietary Names system was initiated by World Health Assembly resolution WHA3.11 in 1950 and has operated since the first list was published in 1953. The WHO assigns each pharmaceutical substance one name that is recognised worldwide and is public property, which is why it is called nonproprietary: anyone may use it to identify the substance. A manufacturer or inventor requests a name, the WHO selects one and publishes it as a proposed INN, and if no objection is raised within four months it becomes a recommended INN. Names for salts and esters are formed from the INN of the active moiety as modified INNs (INNM).

Substances that are pharmacologically related share a common stem, so the name itself shows the group: -pril for ACE inhibitors, -olol for beta blockers, -tinib for tyrosine kinase inhibitors. The WHO publishes the stems in its Stem Book and adds to them as new classes appear. Because stems carry meaning for prescribers, resolution WHA46.19 of 1993 asks that trade marks are not derived from INNs and do not contain their stems.

EU law builds the INN into the definition of a medicine's name. Article 1(21) of Directive 2001/83/EC defines the common name as the INN recommended by the WHO or, if one does not exist, the usual common name, and Article 1(20) allows the name of the product to be that common name accompanied by a trade mark or the name of the marketing authorisation holder, which is how many generics are named. Where a product has an invented name, Article 54(a) still requires the common name on the outer packaging if the product contains up to three active substances. The SmPC states the active substance by its INN in the qualitative and quantitative composition, and safety work such as the EURD list is organised by substance, not by brand.

For a name written as INN plus company name, EMA's naming guideline expects the INN to be used exactly as published, without omissions or abbreviations and with no punctuation between the INN and the company name, and treats all language versions of an INN as the same name. For a generic of a combination product, the order of the active substances follows the reference medicinal product. A proposed invented name is checked against the product's own INN, against other INNs and against the stem list.

What goes wrong

An invented name includes a stem such as -mab or -pril, or is made up largely of parts of the product's own INN, and is refused; a company abbreviates the INN, or uses a salt name where the published INN is for the active moiety, so the name on the pack and in the SmPC do not match; the WHO revises an INN after the dossier was written and the product information is not updated; translations of the INN differ between the national texts of one procedure; and the strength is expressed on the salt in one market and on the base in another, which changes the number printed after the same name. A proposed INN can still attract objections, so a programme that prints packaging before the recommended INN is published takes a risk.

Timing

  1. Request

    The manufacturer or inventor asks the WHO for a name.

  2. Proposed INN

    The selected name is published for comment.

  3. 4 months

    Objection period after publication.

  4. Recommended INN

    With no objection, the name is published as recommended.

The WHO publishes proposed INNs in lists. A four-month objection period follows each publication; if no objection is raised, the name is published as a recommended INN.

What teams do with it in Regunaut

One job in the platform that turn on INN, each part of a wider workflow.

INN: common questions

What is the difference between an INN and a brand name?

The INN identifies the active substance and is public property: every product containing that substance can use it. The brand name, or invented name, identifies one company's product and is usually protected as a trade mark. One INN can therefore sit behind many brand names, and a generic may carry no brand name at all, only the INN and the company name.

What is an INN stem?

A stem is a group of letters shared by the INNs of pharmacologically related substances, such as -olol for beta blockers or -tinib for tyrosine kinase inhibitors. It tells a prescriber which class a substance belongs to. The WHO lists stems in its Stem Book, and regulators object to brand names that contain them.

Can a brand name be based on the INN?

It should not be. World Health Assembly resolution WHA46.19 asks that trade marks are not derived from INNs and do not contain INN stems, and Article 1(20) of Directive 2001/83/EC requires an invented name not to be liable to confusion with the common name. EMA's Name Review Group checks how much of a proposed name overlaps with the INN and whether it contains a stem.

Guides that cover INN

Sources

  1. World Health Organization: Guidance on INN
  2. World Health Organization: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024
  3. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use

Put your INN question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.